(Q83877786)

English

Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study

scientific article published on 14 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

peritoneal carcinoma

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

author name string

Thomas C Krivak

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Kathleen M Darcy

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Chunqiao Tian

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Michael Bookman

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Holly Gallion

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Christine B Ambrosone

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Julie A Deloia

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

14 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

122

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

121-126

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Platinum resistance: the role of DNA repair pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Analysis of CHEK2 gene for ovarian cancer susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.03.027

7 January 2021

Identifiers

10.1016/J.YGYNO.2011.03.027

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496891%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83877786&oldid=1754772468"